Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib
Adam S. Kittai(Icahn School of Medicine at Mount Sinai), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Kerry A. Rogers(The Ohio State University), Seema A. Bhat(The Ohio State University), Michael R. Grever(The Ohio State University Wexner Medical Center), David A. Bond(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Max Yano(The Ohio State University), Ying Huang(Linyi University), Cecelia Miller, John C. Byrd(University of Cincinnati), Daniel J. Goldstein(Montefiore Medical Center), Kyle A. Beckwith
Cited by 21
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia
|The Journal of Experimental Medicine|2001|1.1k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890